Insider sells 11,832 ADRs at Immunocore (NASDAQ: IMCR) in cashless exercise

Rhea-AI Filing Summary

Immunocore Holdings Plc reported an insider sale. A holder executed a same-day cashless exercise and sale of 11,832 ADRs on 03/11/2026, with cash proceeds. The filing also records an earlier sale of 5,965 ADRs on 02/18/2026.

Insights

Corporate Governance Analyst

Routine insider disposition via cashless exercise and sale; timing and proceeds are disclosed.

The filing lists a same-day cashless exercise and sale of 11,832 ADRs on 03/11/2026, and a prior disposition of 5,965 ADRs on 02/18/2026. Cash-flow treatment is shown as cash.

These entries are typical disclosure for Rule 144 notices; material impact depends on holder size relative to total outstanding ADRs, which is not provided in the excerpt. Subsequent filings may provide additional position context.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ADR	J.P. Morgan Securities LLC 270 Park Ave 10th Floor New York NY 10017	11832	385330.11	50387068	03/11/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ADR	03/11/2026	Same Day Cashless Exercise and Sale	Immunocore Holdings Plc (issuer)			11832	03/12/2026	cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
David Berman 4915 Hampden Ln Unit 405 Bethesda MD 20814	ADR	02/18/2026	5965	192951.05

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did Immunocore (IMCR) disclose in this Form 144?

Answer: The Form 144 shows a same-day cashless exercise and sale of 11,832 ADRs on 03/11/2026, and a prior sale of 5,965 ADRs on 02/18/2026. It records proceeds in cash from the March transaction.

Who is the reporting party for the AD R sales in IMCR's filing?

Answer: The excerpt names David Berman with an address in Bethesda, MD, linked to a sale of 5,965 ADRs on 02/18/2026. The March transaction lists the issuer as Immunocore Holdings Plc and sale agent details.

What transaction method is shown for the March 2026 IMCR ADR sale?

Answer: The March 03/11/2026 entry is described as a Same Day Cashless Exercise and Sale, with the form indicating the transaction produced cash proceeds. The security type is listed as ADR traded on NASDAQ.

Does the Form 144 indicate how much cash was received from the sales?

Answer: The filing shows a cash amount associated with each sale line (e.g., 192,951.05 for the February sale), and the March line includes a listed cash figure; the excerpt ties amounts to each transaction row in the notice.